Development of antiobesity medication has not been easy, because of unexpected adverse events
But is GHK-Cu safe across the board
In a Phase 2 trial, patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease were randomly assigned to given placebo, 25 or 50 mg OCA for 6 weeks, it shows increased insulin sensitivity (by 28.0% from baseline with 25 mg OCA (P=0.019) and 20.1% from baseline with 50 mg OCA (P=0.060)), and decreased biological indicators of liver inflammation and fibrosis (NCT00501592)
It's a wild experience
Poreba MA, Dong CX, Li SK, Stahl A, Miner JH, Brubaker PL
Zimmermann, Iodine requirements and the risks and benefits of correcting iodine deficiency in populations